[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fukj4Ml7D8MkCFfXolM8s-_oe4iBQYWLiDOZcpmJRZCE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Gruppo Italiano Malattie EMatologiche dell'Adulto",[4],130,false,32,9,35152,17,54,[14,17,20,22,24,27,30,32],{"name":15,"count":16},"Chronic Lymphocytic Leukemia",15,{"name":18,"count":19},"Chronic Myeloid Leukemia",14,{"name":21,"count":19},"Acute Myeloid Leukemia",{"name":23,"count":9},"Leukemia",{"name":25,"count":26},"Acute Lymphoblastic Leukemia",8,{"name":28,"count":29},"Myelodysplastic Syndromes",5,{"name":31,"count":29},"Acute Promyelocytic Leukemia",{"name":33,"count":34},"AML, Adult",4,[36,41,46,51,56,61,66,70,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04282811","Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy","2023-01-31","Venetoclax",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04763928","Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax","2024-10-25","Venetoclax+Decitabine",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04475731","Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse","2024-11","Ponatinib",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04168502","Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML","2025-04","Gemtuzumab Ozogamicin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05694312","Ibrutinib for the Treatment of AIHA in Patients With CLL\u002FSLL or CLL-like MBL","2025-05","Ibrutinib 420 mg",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06364033","Biological and Clinical Efficacy of Shingrix in Patients With CLL","2025-11","serologic response evaluation",{"nctId":67,"briefTitle":68,"date":69,"intervention":50},"NCT05306301","Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","2026-03-01",{"nctId":71,"briefTitle":72,"date":69,"intervention":73},"NCT04184505","Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)","Azacitidine",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05478512","Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL","2026-05","VenObi+Ven or VenObi+VenZan",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05839392","Novel Approaches to Target MECOM\u002FEVI1 in AML","2026-12","Biological characterization of AML with MECOM or atypical 3q26 rearrangements",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,123,141,164,182,203,255,348,366,390,418,446,467,492,514,558,578,601,658,687,705,723,749,775,817,852,890,912,934,964,986,1011,1029,1052,1076,1094,1117,1141,1166,1184,1202,1227,1252,1276,1294,1319,1337,1355,1373,1391,1409,1427,1445,1483,1501,1519,1537,1555,1573,1591,1609,1627,1645,1663,1687,1705,1723,1748,1773,1797,1815,1840,1858,1899,1935,1961,1993,2019,2045,2077,2124,2159,2187,2209,2231,2253,2280,2302,2330,2357,2380,2403,2426,2451,2469,2487,2505,2523,2541,2565,2589,2613,2640,2664],{"intervention":93,"totalTrials":94,"cells":95},"Ponatinib + Blinatumomab",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":119,"NA":121},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":117},"NCT04722848","Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","ACTIVE_NOT_RECRUITING",[88],"2027-09","2021-09-08",236,[114,115,116],"Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)","ALL, Adult","Philadelphia-Positive ALL",[93,118],"Chemotherapy + Imatinib",{"trials":120,"activeCount":98},[],{"trials":122,"activeCount":98},[],{"intervention":118,"totalTrials":94,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":137,"NA":139},{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":98},[],{"trials":132,"activeCount":94,"soonestReadout":110},[133],{"nctId":106,"briefTitle":107,"status":108,"phases":134,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":135,"interventions":136},[88],[114,115,116],[93,118],{"trials":138,"activeCount":98},[],{"trials":140,"activeCount":98},[],{"intervention":73,"totalTrials":94,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":160,"NA":162},{"trials":144,"activeCount":98},[],{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":94,"soonestReadout":69},[151],{"nctId":71,"briefTitle":72,"status":152,"phases":153,"primaryCompletion":69,"completion":69,"start":154,"enrollment":155,"conditions":156,"interventions":158},"RECRUITING",[88],"2020-11-27",274,[157],"High-risk MDS",[73,159],"Standard Chemotherapy",{"trials":161,"activeCount":98},[],{"trials":163,"activeCount":98},[],{"intervention":159,"totalTrials":94,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":178,"NA":180},{"trials":167,"activeCount":98},[],{"trials":169,"activeCount":98},[],{"trials":171,"activeCount":98},[],{"trials":173,"activeCount":94,"soonestReadout":69},[174],{"nctId":71,"briefTitle":72,"status":152,"phases":175,"primaryCompletion":69,"completion":69,"start":154,"enrollment":155,"conditions":176,"interventions":177},[88],[157],[73,159],{"trials":179,"activeCount":98},[],{"trials":181,"activeCount":98},[],{"intervention":55,"totalTrials":94,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":199,"NA":201},{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":98},[],{"trials":189,"activeCount":98},[],{"trials":191,"activeCount":94,"soonestReadout":54},[192],{"nctId":52,"briefTitle":53,"status":152,"phases":193,"primaryCompletion":54,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},[88],"2027-04","2020-09-24",414,[21],[55],{"trials":200,"activeCount":98},[],{"trials":202,"activeCount":98},[],{"intervention":50,"totalTrials":34,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":239,"PHASE4":241,"NA":243},{"trials":206,"activeCount":98},[],{"trials":208,"activeCount":98},[],{"trials":210,"activeCount":238,"soonestReadout":49},[211,218,226],{"nctId":47,"briefTitle":48,"status":108,"phases":212,"primaryCompletion":49,"completion":49,"start":213,"enrollment":214,"conditions":215,"interventions":217},[87],"2021-05-04",67,[116,216],"Acute Lymphoblastic Leukemia, in Relapse",[50],{"nctId":67,"briefTitle":68,"status":108,"phases":219,"primaryCompletion":69,"completion":220,"start":221,"enrollment":8,"conditions":222,"interventions":225},[87],"2028-07-01","2022-10-05",[223,224],"Chemotherapy","Leukemia, Acute Lymphoblastic",[50],{"nctId":227,"briefTitle":228,"status":229,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":19,"conditions":234,"interventions":237},"NCT02398825","Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib","TERMINATED",[87],"2020-11-13","2022-12-27","2016-06-23",[18,235,236],"Chronic Phase","Adults",[50],2,{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":98},[],{"trials":244,"activeCount":98},[245],{"nctId":246,"briefTitle":247,"status":229,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT02448095","Retrospective Evaluation of CML Patients in the National Compassionate Program",[],"2018-07-17","2015-12-22",38,[18,253],"Philadelphia Positive",[50],{"intervention":256,"totalTrials":257,"cells":258},"Nilotinib",6,{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":320,"PHASE4":332,"NA":346},{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":98},[],{"trials":264,"activeCount":94,"soonestReadout":269},[265,279,293,302],{"nctId":266,"briefTitle":267,"status":152,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":277},"NCT06409936","PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML",[87],"2029-06","2032-06","2025-06-26",160,[274,275,276,18],"CML, Chronic Phase","Chronic Myeloid Leukemia, Chronic Phase","Chronic Myeloid Leukemia, BCR\u002FABL-Positive",[278,256],"Asciminib",{"nctId":280,"briefTitle":281,"status":282,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":291},"NCT01025505","Ph+\u002FBcr-Abl+ ALL Imatinib and Nilotinib Rotational Study","COMPLETED",[87],"2015-12","2020-09-01","2012-06",40,[289,290],"Treatment","Stem Cell Transplantation",[256,292],"Imatinib",{"nctId":294,"briefTitle":295,"status":282,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT00481052","Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase",[87],"2018-04-30","2007-06-23",74,[18],[256],{"nctId":303,"briefTitle":304,"status":282,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":311},"NCT00769327","Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia",[87],"2014-10","2014-10-10","2009-02-09",129,[23],[312,313,314,315,316,317,318,319],"imatinib mesylate","nilotinib","cytogenetic analysis","fluorescence in situ hybridization","microarray analysis","mutation analysis","polymerase chain reaction","polymorphism analysis",{"trials":321,"activeCount":98},[322],{"nctId":323,"briefTitle":324,"status":282,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT01535391","Nilotinib in PH+, BCR-, ABL+ CML Patients",[88],"2014-11","2018-04-27","2012-01",109,[18],[256],{"trials":333,"activeCount":98},[334],{"nctId":335,"briefTitle":336,"status":337,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT02602314","Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia","UNKNOWN",[89],"2023-02","2024-02","2016-11-11",450,[344],"Chronyc Myeloid Leukemia",[292,256],{"trials":347,"activeCount":98},[],{"intervention":278,"totalTrials":94,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":98},[],{"trials":355,"activeCount":94,"soonestReadout":269},[356],{"nctId":266,"briefTitle":267,"status":152,"phases":357,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":358,"interventions":359},[87],[274,275,276,18],[278,256],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":98},[],{"intervention":60,"totalTrials":94,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":94,"soonestReadout":59},[374],{"nctId":57,"briefTitle":58,"status":152,"phases":375,"primaryCompletion":59,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":383},[87],"2026-11","2023-11-24",45,[380,15,381,382],"Autoimmune Hemolytic Anemia","Small Lymphocytic Lymphoma","Monoclonal B-Cell Lymphocytosis CLL-Type",[60],{"trials":385,"activeCount":98},[],{"trials":387,"activeCount":98},[],{"trials":389,"activeCount":98},[],{"intervention":391,"totalTrials":94,"cells":392},"Teclistamab",{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":98},[],{"trials":398,"activeCount":94,"soonestReadout":404},[399],{"nctId":400,"briefTitle":401,"status":402,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":411},"NCT06880601","Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R\u002FR Multiple Myeloma","NOT_YET_RECRUITING",[87],"2029-11-01","2025-11-01",52,[408,409,410],"Multiple Myleoma","Multiple Myeloma in Relapse","Multiple Myeloma Refractory",[391],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":98},[],{"intervention":419,"totalTrials":94,"cells":420},"Gilteritinib",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":440,"PHASE4":442,"NA":444},{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":98},[],{"trials":426,"activeCount":94,"soonestReadout":431},[427],{"nctId":428,"briefTitle":429,"status":402,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":439},"NCT06667973","Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia",[87],"2028-08","2030-06","2025-06",80,[21,436,437,438],"FLT3 Gene Mutation","Adult AML","Diagnosis",[419],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"intervention":45,"totalTrials":94,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":98},[],{"trials":453,"activeCount":94,"soonestReadout":44},[454],{"nctId":42,"briefTitle":43,"status":108,"phases":455,"primaryCompletion":44,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":460},[87],"2026-04","2021-12-03",101,[21],[45],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"intervention":468,"totalTrials":94,"cells":469},"Daratumumab plus chemotherapy according to the national treatment program",{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":486,"PHASE4":488,"NA":490},{"trials":471,"activeCount":98},[],{"trials":473,"activeCount":98},[],{"trials":475,"activeCount":94,"soonestReadout":480},[476],{"nctId":477,"briefTitle":478,"status":108,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":485},"NCT06253637","Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program",[87],"2029-10","2024-10-17",31,[484],"T-Lymphocytic Leukemia, Acute",[468],{"trials":487,"activeCount":98},[],{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":495,"activeCount":98},[],{"trials":497,"activeCount":98},[],{"trials":499,"activeCount":94,"soonestReadout":77},[500],{"nctId":75,"briefTitle":76,"status":108,"phases":501,"primaryCompletion":77,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},[87],"2027-07","2023-07-21",78,[506,15],"High Risk CLL",[78],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"trials":513,"activeCount":98},[],{"intervention":40,"totalTrials":515,"cells":516},3,{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":98},[523,534],{"nctId":524,"briefTitle":525,"status":282,"phases":526,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":532},"NCT03455517","Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia",[87],"2021-09-05","2023-05-11","2018-10-31",77,[18],[40,533],"Rituximab",{"nctId":535,"briefTitle":536,"status":337,"phases":537,"primaryCompletion":538,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":542},"NCT03455504","Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia",[87],"2025-01","2018-10-26",124,[21],[40],{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":98},[],{"trials":548,"activeCount":94,"soonestReadout":39},[549],{"nctId":37,"briefTitle":38,"status":152,"phases":550,"primaryCompletion":39,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":557},[],"2025-10-31","2020-07-24",321,[15,555,556],"Relapse Leukemia","Refractory Leukemia",[40],{"intervention":83,"totalTrials":94,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[],{"trials":567,"activeCount":98},[],{"trials":569,"activeCount":98},[],{"trials":571,"activeCount":94,"soonestReadout":82},[572],{"nctId":80,"briefTitle":81,"status":152,"phases":573,"primaryCompletion":82,"completion":82,"start":574,"enrollment":575,"conditions":576,"interventions":577},[90],"2023-12-13",24,[33],[83],{"intervention":65,"totalTrials":94,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":98},[],{"trials":587,"activeCount":98},[],{"trials":589,"activeCount":98},[],{"trials":591,"activeCount":94,"soonestReadout":64},[592],{"nctId":62,"briefTitle":63,"status":402,"phases":593,"primaryCompletion":64,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":600},[90],"2028-10","2024-08",312,[15,381,598,599],"CLL-like MBL","Varicella-zoster Virus Reactivation",[65],{"intervention":602,"totalTrials":515,"cells":603},"idarubicin",{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":622,"PHASE3":640,"PHASE4":654,"NA":656},{"trials":605,"activeCount":98},[],{"trials":607,"activeCount":98},[608],{"nctId":609,"briefTitle":610,"status":282,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":617},"NCT01154439","Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",[86],"2013-05","2015-09-15","2010-10",11,[23],[618,619,620,602,621],"cytarabine","etoposide","everolimus","mitoxantrone hydrochloride",{"trials":623,"activeCount":98},[624],{"nctId":625,"briefTitle":626,"status":282,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":632},"NCT00458848","Chemotherapy With or Without Imatinib and\u002For Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia",[87],"2014-03","2004-10",470,[23],[633,634,619,602,312,635,636,637,621,638,639],"asparaginase","daunorubicin hydrochloride","mercaptopurine","methotrexate","methylprednisolone","prednisone","vincristine sulfate",{"trials":641,"activeCount":98},[642],{"nctId":643,"briefTitle":644,"status":282,"phases":645,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":651},"NCT00482833","Phase III Trial in Acute Promyelocytic Leukemia Patients",[88],"2012-09","2019-10-17","2007-08",276,[23],[652,602,635,636,653,653],"arsenic trioxide","all-trans retinoic acid",{"trials":655,"activeCount":98},[],{"trials":657,"activeCount":98},[],{"intervention":659,"totalTrials":94,"cells":660},"Daunorubicin",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":683,"NA":685},{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[669],{"nctId":670,"briefTitle":671,"status":337,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT04174612","AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance",[88],"2022-12","2025-08-01","2020-04-24",172,[678],"Acute Myeloid Leukemia With FLT3\u002FITD Mutation",[680,659,681,682],"Cytarabine","Midostaurin","Cytarabine HD",{"trials":684,"activeCount":98},[],{"trials":686,"activeCount":98},[],{"intervention":681,"totalTrials":94,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":701,"NA":703},{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":98},[697],{"nctId":670,"briefTitle":671,"status":337,"phases":698,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":699,"interventions":700},[88],[678],[680,659,681,682],{"trials":702,"activeCount":98},[],{"trials":704,"activeCount":98},[],{"intervention":682,"totalTrials":94,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":719,"NA":721},{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[715],{"nctId":670,"briefTitle":671,"status":337,"phases":716,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":717,"interventions":718},[88],[678],[680,659,681,682],{"trials":720,"activeCount":98},[],{"trials":722,"activeCount":98},[],{"intervention":724,"totalTrials":94,"cells":725},"DaunoXome",{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":745,"NA":747},{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":98},[],{"trials":733,"activeCount":98},[734],{"nctId":735,"briefTitle":736,"status":282,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"conditions":740,"interventions":743},"NCT00589082","DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML",[88],"2005-11","2001-10",[741,742],"AML","Elderly",[724,744],"Daunorubicine",{"trials":746,"activeCount":98},[],{"trials":748,"activeCount":98},[],{"intervention":750,"totalTrials":94,"cells":751},"Deferasirox",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":771,"NA":773},{"trials":753,"activeCount":98},[],{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"trials":759,"activeCount":98},[760],{"nctId":761,"briefTitle":762,"status":282,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":770},"NCT00469560","Safety, Tolerability, and Efficacy of Deferasirox in MDS",[88],"2010-03","2013-11","2007-06",158,[28,769],"Hemosiderosis",[750],{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":98},[],{"intervention":533,"totalTrials":515,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[783,787,800],{"nctId":524,"briefTitle":525,"status":282,"phases":784,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":785,"interventions":786},[87],[18],[40,533],{"nctId":788,"briefTitle":789,"status":282,"phases":790,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":798},"NCT02232386","Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia",[87],"2018-04","2024-04-16","2015-03-02",156,[796,797],"Chronic Lymphocyte Leukemia","Adult Patients",[799,533],"Ibrutinib",{"nctId":801,"briefTitle":802,"status":229,"phases":803,"primaryCompletion":804,"completion":804,"start":805,"enrollment":29,"conditions":806,"interventions":809},"NCT03804372","The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma\u002FChronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide",[87],"2024-05-22","2020-07-07",[807,808],"Large-B-cell Diffuse Lymphoma","Chronic Lymphoid Leukemia",[533,223,810],"Tenofovir alafenamide",{"trials":812,"activeCount":98},[],{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[],{"intervention":818,"totalTrials":238,"cells":819},"Dasatinib",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":846,"PHASE4":848,"NA":850},{"trials":821,"activeCount":98},[],{"trials":823,"activeCount":98},[],{"trials":825,"activeCount":98},[826,836],{"nctId":827,"briefTitle":828,"status":282,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":835},"NCT00391989","Treatment of Adult Ph+ LAL With BMS-354825",[87],"2008-09","2006-09",53,[834],"Lymphoblastic Leukemia, Acute",[818],{"nctId":837,"briefTitle":838,"status":337,"phases":839,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":843,"interventions":844},"NCT02744768","D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia",[87],"2021-06","2017-05-31",60,[25],[818,845],"Blinatumomab",{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[],{"trials":851,"activeCount":98},[],{"intervention":853,"totalTrials":238,"cells":854},"Fludarabine",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[861,871],{"nctId":862,"briefTitle":863,"status":282,"phases":864,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":869},"NCT00462332","Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia",[87],"2011-06","2007-05",86,[23],[853,870,870,853,870,870],"Campath",{"nctId":872,"briefTitle":873,"status":282,"phases":874,"primaryCompletion":875,"completion":876,"start":877,"enrollment":434,"conditions":878,"interventions":881},"NCT01762202","Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.",[87],"2015-11","2018-10","2013-11-05",[879,880],"B-cell Lymphoid Leukemia","Young Patients",[882,853,883],"Cyclophosphamide","Ofatumumab",{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[],{"intervention":619,"totalTrials":238,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":900,"PHASE3":906,"PHASE4":908,"NA":910},{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[896],{"nctId":609,"briefTitle":610,"status":282,"phases":897,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":898,"interventions":899},[86],[23],[618,619,620,602,621],{"trials":901,"activeCount":98},[902],{"nctId":625,"briefTitle":626,"status":282,"phases":903,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":904,"interventions":905},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":907,"activeCount":98},[],{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":98},[],{"intervention":621,"totalTrials":238,"cells":913},{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":922,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":915,"activeCount":98},[],{"trials":917,"activeCount":98},[918],{"nctId":609,"briefTitle":610,"status":282,"phases":919,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":920,"interventions":921},[86],[23],[618,619,620,602,621],{"trials":923,"activeCount":98},[924],{"nctId":625,"briefTitle":626,"status":282,"phases":925,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":926,"interventions":927},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[],{"intervention":883,"totalTrials":238,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":937,"activeCount":98},[],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":98},[942,946],{"nctId":872,"briefTitle":873,"status":282,"phases":943,"primaryCompletion":875,"completion":876,"start":877,"enrollment":434,"conditions":944,"interventions":945},[87],[879,880],[882,853,883],{"nctId":947,"briefTitle":948,"status":282,"phases":949,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":956},"NCT01244451","GIMEMA CLL0809 Study (BendOfa)",[87],"2014-07","2010-12",49,[954,955],"Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or","Patients With CLL Refractory (SD, PD or CR\u002FPR \u003C 6 Months) Following no More Than Two Prior Treatment Lines",[883,957],"Bendamustine",{"trials":959,"activeCount":98},[],{"trials":961,"activeCount":98},[],{"trials":963,"activeCount":98},[],{"intervention":312,"totalTrials":238,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[972,976],{"nctId":625,"briefTitle":626,"status":282,"phases":973,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":974,"interventions":975},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"nctId":303,"briefTitle":304,"status":282,"phases":977,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":978,"interventions":979},[87],[23],[312,313,314,315,316,317,318,319],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[],{"trials":985,"activeCount":98},[],{"intervention":987,"totalTrials":94,"cells":988},"Ibrutinib + ofatumumab",{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":98},[995],{"nctId":996,"briefTitle":997,"status":282,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1004},"NCT02388048","Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia",[87],"2024-04-03","2015-10",19,[1003],"Leukemia, Lymphoblastic, Chronic",[987],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[],{"intervention":870,"totalTrials":94,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1014,"activeCount":98},[],{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[1019],{"nctId":862,"briefTitle":863,"status":282,"phases":1020,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":1021,"interventions":1022},[87],[23],[853,870,870,853,870,870],{"trials":1024,"activeCount":98},[],{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[],{"intervention":1030,"totalTrials":94,"cells":1031},"Lenalidomide; Chlorambucil",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[1038],{"nctId":1039,"briefTitle":1040,"status":229,"phases":1041,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":9,"conditions":1044,"interventions":1045},"NCT01403246","Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)",[86,87],"2015-01","2011-11",[15],[1030],{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"intervention":1053,"totalTrials":94,"cells":1054},"clofarabine",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"trials":1060,"activeCount":98},[1061],{"nctId":1062,"briefTitle":1063,"status":282,"phases":1064,"primaryCompletion":286,"completion":1065,"start":1066,"enrollment":842,"conditions":1067,"interventions":1068},"NCT00775593","Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia",[87],"2013-10-23","2008-12",[23],[1053,1069],"temsirolimus",{"trials":1071,"activeCount":98},[],{"trials":1073,"activeCount":98},[],{"trials":1075,"activeCount":98},[],{"intervention":1069,"totalTrials":94,"cells":1077},{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1088,"PHASE4":1090,"NA":1092},{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[1084],{"nctId":1062,"briefTitle":1063,"status":282,"phases":1085,"primaryCompletion":286,"completion":1065,"start":1066,"enrollment":842,"conditions":1086,"interventions":1087},[87],[23],[1053,1069],{"trials":1089,"activeCount":98},[],{"trials":1091,"activeCount":98},[],{"trials":1093,"activeCount":98},[],{"intervention":1095,"totalTrials":94,"cells":1096},"High-dose anthracycline",{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1098,"activeCount":98},[],{"trials":1100,"activeCount":98},[],{"trials":1102,"activeCount":98},[1103],{"nctId":1104,"briefTitle":1105,"status":337,"phases":1106,"primaryCompletion":1107,"completion":1107,"start":1108,"conditions":1109,"interventions":1110},"NCT00439920","GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.",[87],"2018-12","1996-10",[25],[1095],{"trials":1112,"activeCount":98},[],{"trials":1114,"activeCount":98},[],{"trials":1116,"activeCount":98},[],{"intervention":1118,"totalTrials":94,"cells":1119},"Clofarabine, Cyclophosphamide",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[1126],{"nctId":1127,"briefTitle":1128,"status":282,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":1132,"conditions":1133,"interventions":1134},"NCT01462253","Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults",[87],"2017-03-11","2012-10",35,[25],[1118],{"trials":1136,"activeCount":98},[],{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"intervention":1142,"totalTrials":94,"cells":1143},"5-Azacytidine",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1145,"activeCount":98},[],{"trials":1147,"activeCount":98},[],{"trials":1149,"activeCount":98},[1150],{"nctId":1151,"briefTitle":1152,"status":282,"phases":1153,"primaryCompletion":1154,"completion":1154,"start":866,"enrollment":1155,"conditions":1156,"interventions":1157},"NCT00439673","PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS",[87],"2010-07",62,[28],[1142,1158,1159],"Valproic Acid","ATRA",{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[],{"trials":1165,"activeCount":98},[],{"intervention":1158,"totalTrials":94,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1169,"activeCount":98},[],{"trials":1171,"activeCount":98},[],{"trials":1173,"activeCount":98},[1174],{"nctId":1151,"briefTitle":1152,"status":282,"phases":1175,"primaryCompletion":1154,"completion":1154,"start":866,"enrollment":1155,"conditions":1176,"interventions":1177},[87],[28],[1142,1158,1159],{"trials":1179,"activeCount":98},[],{"trials":1181,"activeCount":98},[],{"trials":1183,"activeCount":98},[],{"intervention":1159,"totalTrials":94,"cells":1185},{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1196,"PHASE4":1198,"NA":1200},{"trials":1187,"activeCount":98},[],{"trials":1189,"activeCount":98},[],{"trials":1191,"activeCount":98},[1192],{"nctId":1151,"briefTitle":1152,"status":282,"phases":1193,"primaryCompletion":1154,"completion":1154,"start":866,"enrollment":1155,"conditions":1194,"interventions":1195},[87],[28],[1142,1158,1159],{"trials":1197,"activeCount":98},[],{"trials":1199,"activeCount":98},[],{"trials":1201,"activeCount":98},[],{"intervention":1203,"totalTrials":94,"cells":1204},"Bosutinib",{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[1211],{"nctId":1212,"briefTitle":1213,"status":282,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT02810990","Bosutinib in Elderly Chronic Myeloid Leukemia",[87],"2020-04-30","2022-06-22","2016-11-17",65,[18],[1203],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"intervention":1228,"totalTrials":94,"cells":1229},"Velcade",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":98},[],{"trials":1235,"activeCount":98},[1236],{"nctId":1237,"briefTitle":1238,"status":229,"phases":1239,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT00440076","Velcade in Myelodysplastic Syndrome - Pilot Study",[87],"2008-03","2006-08",28,[1244],"MDS",[1228],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":98},[],{"intervention":1253,"totalTrials":94,"cells":1254},"Venetoclax+azacitidine",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":98},[],{"trials":1260,"activeCount":98},[1261],{"nctId":1262,"briefTitle":1263,"status":337,"phases":1264,"primaryCompletion":538,"completion":538,"start":1265,"enrollment":1132,"conditions":1266,"interventions":1269},"NCT04867928","Venetoclax and Azacitidine for the Management of Molecular Relapse\u002FProgression in Adult NPM1-mutated Acute Myeloid Leukemia",[87],"2022-03-01",[21,1267,1268],"Acute Myeloid Leukemia, in Relapse","NPM1 Mutation",[1253],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"intervention":845,"totalTrials":94,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[1284],{"nctId":837,"briefTitle":838,"status":337,"phases":1285,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":1286,"interventions":1287},[87],[25],[818,845],{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"intervention":1295,"totalTrials":94,"cells":1296},"Fludarabine phosphate",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1298,"activeCount":98},[],{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":98},[1303],{"nctId":1304,"briefTitle":1305,"status":282,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT00727415","Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy",[86,87],"2016-01","2008-02",42,[15],[882,1295,1312],"Lenalidomide",{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[],{"intervention":1312,"totalTrials":94,"cells":1320},{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":98},[1327],{"nctId":1304,"briefTitle":1305,"status":282,"phases":1328,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1329,"interventions":1330},[86,87],[15],[882,1295,1312],{"trials":1332,"activeCount":98},[],{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":98},[],{"intervention":314,"totalTrials":94,"cells":1338},{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[],{"trials":1344,"activeCount":98},[1345],{"nctId":303,"briefTitle":304,"status":282,"phases":1346,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":1347,"interventions":1348},[87],[23],[312,313,314,315,316,317,318,319],{"trials":1350,"activeCount":98},[],{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"intervention":315,"totalTrials":94,"cells":1356},{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1367,"PHASE4":1369,"NA":1371},{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":98},[1363],{"nctId":303,"briefTitle":304,"status":282,"phases":1364,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":1365,"interventions":1366},[87],[23],[312,313,314,315,316,317,318,319],{"trials":1368,"activeCount":98},[],{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"intervention":316,"totalTrials":94,"cells":1374},{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1376,"activeCount":98},[],{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":98},[1381],{"nctId":303,"briefTitle":304,"status":282,"phases":1382,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":1383,"interventions":1384},[87],[23],[312,313,314,315,316,317,318,319],{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"intervention":317,"totalTrials":94,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[1399],{"nctId":303,"briefTitle":304,"status":282,"phases":1400,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":1401,"interventions":1402},[87],[23],[312,313,314,315,316,317,318,319],{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"intervention":318,"totalTrials":94,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[1417],{"nctId":303,"briefTitle":304,"status":282,"phases":1418,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":1419,"interventions":1420},[87],[23],[312,313,314,315,316,317,318,319],{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"intervention":319,"totalTrials":94,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[1435],{"nctId":303,"briefTitle":304,"status":282,"phases":1436,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":1437,"interventions":1438},[87],[23],[312,313,314,315,316,317,318,319],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":98},[],{"intervention":1446,"totalTrials":94,"cells":1447},"Prephase PDN + CY",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1477,"PHASE4":1479,"NA":1481},{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":98},[1454],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1457,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1462,"interventions":1467},"NCT02067143","MRD\u002FRisk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate",[87],"2016-10-07","2020-12-07","2014-05-20",204,[1463,1464,1465,1466],"Untreated Philadelphia Positive Acute Lymphoblastic Leukemia","De Novo","Secondary","Low-dose Corticosteroids Pretreatment",[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],"Cycle 1 Induction","Cycle 2 Induction \u002F Early consolidation","Cycle 3 Early consolidation","Cycle 4 Consolidation","Cycle 5 Consolidation","Cycle 6 Consolidation","Cycle 7 Consolidation","Cycle 8 Reinduction","Maintenance",{"trials":1478,"activeCount":98},[],{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[],{"intervention":1468,"totalTrials":94,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[],{"trials":1490,"activeCount":98},[1491],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1492,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1493,"interventions":1494},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1496,"activeCount":98},[],{"trials":1498,"activeCount":98},[],{"trials":1500,"activeCount":98},[],{"intervention":1469,"totalTrials":94,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1513,"PHASE4":1515,"NA":1517},{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":98},[],{"trials":1508,"activeCount":98},[1509],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1510,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1511,"interventions":1512},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[],{"trials":1518,"activeCount":98},[],{"intervention":1470,"totalTrials":94,"cells":1520},{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1525,"PHASE3":1531,"PHASE4":1533,"NA":1535},{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[],{"trials":1526,"activeCount":98},[1527],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1528,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1529,"interventions":1530},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":98},[],{"trials":1536,"activeCount":98},[],{"intervention":1471,"totalTrials":94,"cells":1538},{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1549,"PHASE4":1551,"NA":1553},{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[1545],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1546,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1547,"interventions":1548},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[],{"trials":1554,"activeCount":98},[],{"intervention":1472,"totalTrials":94,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1558,"activeCount":98},[],{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":98},[1563],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1564,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1565,"interventions":1566},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":98},[],{"intervention":1473,"totalTrials":94,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1576,"activeCount":98},[],{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[1581],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1582,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1583,"interventions":1584},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1586,"activeCount":98},[],{"trials":1588,"activeCount":98},[],{"trials":1590,"activeCount":98},[],{"intervention":1474,"totalTrials":94,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[1599],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1600,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1601,"interventions":1602},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"trials":1608,"activeCount":98},[],{"intervention":1475,"totalTrials":94,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1612,"activeCount":98},[],{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[1617],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1618,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1619,"interventions":1620},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1622,"activeCount":98},[],{"trials":1624,"activeCount":98},[],{"trials":1626,"activeCount":98},[],{"intervention":1476,"totalTrials":94,"cells":1628},{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1630,"activeCount":98},[],{"trials":1632,"activeCount":98},[],{"trials":1634,"activeCount":98},[1635],{"nctId":1455,"briefTitle":1456,"status":282,"phases":1636,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":1461,"conditions":1637,"interventions":1638},[87],[1463,1464,1465,1466],[1446,1468,1469,1470,1471,1472,1473,1474,1475,1476],{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[],{"intervention":957,"totalTrials":94,"cells":1646},{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[1653],{"nctId":947,"briefTitle":948,"status":282,"phases":1654,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":1655,"interventions":1656},[87],[954,955],[883,957],{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"intervention":1664,"totalTrials":94,"cells":1665},"tagraxofusp",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":98},[],{"trials":1671,"activeCount":98},[1672],{"nctId":1673,"briefTitle":1674,"status":229,"phases":1675,"primaryCompletion":1676,"completion":1676,"start":1677,"enrollment":1678,"conditions":1679,"interventions":1680},"NCT04342962","Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia",[87],"2024-01-18","2021-02-16",25,[21],[1664],{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[],{"intervention":223,"totalTrials":94,"cells":1688},{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1690,"activeCount":98},[],{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":98},[1695],{"nctId":801,"briefTitle":802,"status":229,"phases":1696,"primaryCompletion":804,"completion":804,"start":805,"enrollment":29,"conditions":1697,"interventions":1698},[87],[807,808],[533,223,810],{"trials":1700,"activeCount":98},[],{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"intervention":810,"totalTrials":94,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1717,"PHASE4":1719,"NA":1721},{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":98},[1713],{"nctId":801,"briefTitle":802,"status":229,"phases":1714,"primaryCompletion":804,"completion":804,"start":805,"enrollment":29,"conditions":1715,"interventions":1716},[87],[807,808],[533,223,810],{"trials":1718,"activeCount":98},[],{"trials":1720,"activeCount":98},[],{"trials":1722,"activeCount":98},[],{"intervention":1724,"totalTrials":94,"cells":1725},"Bortezomib",{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[1732],{"nctId":1733,"briefTitle":1734,"status":282,"phases":1735,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1741},"NCT01696474","Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease",[87],"2017-03-27","2012-12",21,[1740],"Refractory Cold Agglutinin Disease",[1724],{"trials":1743,"activeCount":98},[],{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[],{"intervention":1749,"totalTrials":94,"cells":1750},"Inotuzumab Ozogamicin",{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1755,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1752,"activeCount":98},[],{"trials":1754,"activeCount":98},[],{"trials":1756,"activeCount":98},[1757],{"nctId":1758,"briefTitle":1759,"status":337,"phases":1760,"primaryCompletion":1761,"completion":1761,"start":1762,"enrollment":1763,"conditions":1764,"interventions":1766},"NCT03610438","Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia",[87],"2022-11","2019-10-30",76,[1765],"Acute Lymphoid Leukemia",[1749,1749],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":98},[],{"intervention":1774,"totalTrials":94,"cells":1775},"bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine",{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1777,"activeCount":98},[],{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[1782],{"nctId":1783,"briefTitle":1784,"status":282,"phases":1785,"primaryCompletion":950,"completion":950,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT00466726","Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia",[87],"2007-03",57,[23],[1774,1790],"sargramostim",{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"trials":1796,"activeCount":98},[],{"intervention":1790,"totalTrials":94,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":98},[1805],{"nctId":1783,"briefTitle":1784,"status":282,"phases":1806,"primaryCompletion":950,"completion":950,"start":1786,"enrollment":1787,"conditions":1807,"interventions":1808},[87],[23],[1774,1790],{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"intervention":1816,"totalTrials":94,"cells":1817},"Chemotherapy + Blinatumomab",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1819,"activeCount":98},[],{"trials":1821,"activeCount":98},[],{"trials":1823,"activeCount":98},[1824],{"nctId":1825,"briefTitle":1826,"status":282,"phases":1827,"primaryCompletion":1828,"completion":1828,"start":1829,"enrollment":1830,"conditions":1831,"interventions":1833},"NCT03367299","Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia",[87],"2024-09-02","2018-06-08",149,[1765,1832],"Philadelphia Chromosome-Negative B-Cell Precursor",[1816],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"intervention":620,"totalTrials":94,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1850,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[1846],{"nctId":609,"briefTitle":610,"status":282,"phases":1847,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1848,"interventions":1849},[86],[23],[618,619,620,602,621],{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[],{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"intervention":292,"totalTrials":34,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1880,"PHASE4":1882,"NA":1888},{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[1866,1870],{"nctId":280,"briefTitle":281,"status":282,"phases":1867,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":1868,"interventions":1869},[87],[289,290],[256,292],{"nctId":1871,"briefTitle":1872,"status":282,"phases":1873,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":1877,"conditions":1878,"interventions":1879},"NCT00376467","STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia",[87],"2010-06","2011-02","2001-12",105,[25],[292],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[1884],{"nctId":335,"briefTitle":336,"status":337,"phases":1885,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":1886,"interventions":1887},[89],[344],[292,256],{"trials":1889,"activeCount":98},[1890],{"nctId":1891,"briefTitle":1892,"status":282,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1001,"conditions":1896,"interventions":1898},"NCT01475110","Observational Study in Adults With Imatinib-resistant\u002FIntolerant Chronic Myeloid Leukemia Treated With Nilotinib",[],"2016-11-24","2012-09-13",[1897],"Chronic Myeloid Leukaemia",[292],{"intervention":618,"totalTrials":515,"cells":1900},{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1909,"PHASE3":1911,"PHASE4":1917,"NA":1919},{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[1905],{"nctId":609,"briefTitle":610,"status":282,"phases":1906,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1907,"interventions":1908},[86],[23],[618,619,620,602,621],{"trials":1910,"activeCount":98},[],{"trials":1912,"activeCount":98},[1913],{"nctId":670,"briefTitle":671,"status":337,"phases":1914,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":1915,"interventions":1916},[88],[678],[680,659,681,682],{"trials":1918,"activeCount":98},[],{"trials":1920,"activeCount":98},[1921],{"nctId":1922,"briefTitle":1923,"status":282,"phases":1924,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":1927,"interventions":1928},"NCT01156883","Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia",[90],"2017-10-31","2010-04",[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],"cyclophosphamide","dexamethasone","doxorubicin hydrochloride","ifosfamide","thioguanine","vindesine",{"intervention":882,"totalTrials":515,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[1943,1947],{"nctId":872,"briefTitle":873,"status":282,"phases":1944,"primaryCompletion":875,"completion":876,"start":877,"enrollment":434,"conditions":1945,"interventions":1946},[87],[879,880],[882,853,883],{"nctId":1304,"briefTitle":1305,"status":282,"phases":1948,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1949,"interventions":1950},[86,87],[15],[882,1295,1312],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[1957],{"nctId":1922,"briefTitle":1923,"status":282,"phases":1958,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":1959,"interventions":1960},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":633,"totalTrials":515,"cells":1962},{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1967,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[1969,1973],{"nctId":625,"briefTitle":626,"status":282,"phases":1970,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":1971,"interventions":1972},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"nctId":1974,"briefTitle":1975,"status":229,"phases":1976,"primaryCompletion":1977,"completion":1977,"start":1978,"enrollment":1979,"conditions":1980,"interventions":1981},"NCT03668392","Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)",[87],"2021-12-31","2020-06-25",7,[25],[1982],"Asparaginase",{"trials":1984,"activeCount":98},[],{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":98},[1989],{"nctId":1922,"briefTitle":1923,"status":282,"phases":1990,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":1991,"interventions":1992},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":635,"totalTrials":515,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2005,"PHASE4":2011,"NA":2013},{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":98},[2001],{"nctId":625,"briefTitle":626,"status":282,"phases":2002,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":2003,"interventions":2004},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":2006,"activeCount":98},[2007],{"nctId":643,"briefTitle":644,"status":282,"phases":2008,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":2009,"interventions":2010},[88],[23],[652,602,635,636,653,653],{"trials":2012,"activeCount":98},[],{"trials":2014,"activeCount":98},[2015],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2016,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2017,"interventions":2018},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":636,"totalTrials":515,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2031,"PHASE4":2037,"NA":2039},{"trials":2022,"activeCount":98},[],{"trials":2024,"activeCount":98},[],{"trials":2026,"activeCount":98},[2027],{"nctId":625,"briefTitle":626,"status":282,"phases":2028,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":2029,"interventions":2030},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":2032,"activeCount":98},[2033],{"nctId":643,"briefTitle":644,"status":282,"phases":2034,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":2035,"interventions":2036},[88],[23],[652,602,635,636,653,653],{"trials":2038,"activeCount":98},[],{"trials":2040,"activeCount":98},[2041],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2042,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2043,"interventions":2044},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":638,"totalTrials":515,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2057,"PHASE4":2069,"NA":2071},{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[2053],{"nctId":625,"briefTitle":626,"status":282,"phases":2054,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":2055,"interventions":2056},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":2058,"activeCount":98},[2059],{"nctId":2060,"briefTitle":2061,"status":282,"phases":2062,"primaryCompletion":2063,"completion":2063,"start":2064,"enrollment":2065,"conditions":2066,"interventions":2068},"NCT00657410","Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura",[88],"2016-02","2008-04",150,[2067],"Nonneoplastic Condition",[1930,638],{"trials":2070,"activeCount":98},[],{"trials":2072,"activeCount":98},[2073],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2074,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2075,"interventions":2076},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":2078,"totalTrials":515,"cells":2079},"Eltrombopag",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2081,"activeCount":98},[],{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":98},[2086,2096],{"nctId":2087,"briefTitle":2088,"status":282,"phases":2089,"primaryCompletion":2090,"completion":2090,"start":2091,"enrollment":2092,"conditions":2093,"interventions":2095},"NCT01791101","Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.",[87],"2020-06-26","2013-09-16",10,[2094],"Thrombocytopenia",[2078],{"nctId":2097,"briefTitle":2098,"status":282,"phases":2099,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":2103,"conditions":2104,"interventions":2106},"NCT02402998","Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia",[87],"2018-05-22","2019-08-28","2016-02-24",55,[2105],"Primacy Immune Thrombocytopenia",[2078],{"trials":2108,"activeCount":98},[],{"trials":2110,"activeCount":98},[],{"trials":2112,"activeCount":98},[2113],{"nctId":2114,"briefTitle":2115,"status":282,"phases":2116,"primaryCompletion":2117,"completion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2122},"NCT02298075","Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia",[],"2019-04-17","2016-04",148,[2121],"Immune Thrombocytopenia",[2078,2123],"Romiplostin",{"intervention":653,"totalTrials":515,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2140,"PHASE4":2146,"NA":2148},{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[2132],{"nctId":2133,"briefTitle":2134,"status":337,"phases":2135,"start":2136,"enrollment":2137,"conditions":2138,"interventions":2139},"NCT01064570","AIDA 2000 Guidelines",[87],"2000-05",600,[31],[653],{"trials":2141,"activeCount":98},[2142],{"nctId":643,"briefTitle":644,"status":282,"phases":2143,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":2144,"interventions":2145},[88],[23],[652,602,635,636,653,653],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[2150],{"nctId":2151,"briefTitle":2152,"status":337,"phases":2153,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":2156,"conditions":2157,"interventions":2158},"NCT01064557","\"AIDA\" Protocol (LAP 0493)",[90],"2020-12","1993-10",1068,[23],[653],{"intervention":2160,"totalTrials":238,"cells":2161},"Arsenic Trioxide",{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2168,"PHASE4":2174,"NA":2176},{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"trials":2169,"activeCount":98},[2170],{"nctId":643,"briefTitle":644,"status":282,"phases":2171,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":2172,"interventions":2173},[88],[23],[652,602,635,636,653,653],{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[2178],{"nctId":2179,"briefTitle":2180,"status":337,"phases":2181,"primaryCompletion":2182,"completion":2182,"start":2183,"enrollment":2184,"conditions":2185,"interventions":2186},"NCT03751917","Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia",[],"2024-12","2020-04-14",100,[31],[2160],{"intervention":634,"totalTrials":238,"cells":2188},{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2199,"PHASE4":2201,"NA":2203},{"trials":2190,"activeCount":98},[],{"trials":2192,"activeCount":98},[],{"trials":2194,"activeCount":98},[2195],{"nctId":625,"briefTitle":626,"status":282,"phases":2196,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":2197,"interventions":2198},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":2200,"activeCount":98},[],{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":98},[2205],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2206,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2207,"interventions":2208},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":637,"totalTrials":238,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[2217],{"nctId":625,"briefTitle":626,"status":282,"phases":2218,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":2219,"interventions":2220},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[2227],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2228,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2229,"interventions":2230},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":639,"totalTrials":238,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[],{"trials":2238,"activeCount":98},[2239],{"nctId":625,"briefTitle":626,"status":282,"phases":2240,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":2241,"interventions":2242},[87],[23],[633,634,619,602,312,635,636,637,621,638,639],{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[2249],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2250,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2251,"interventions":2252},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":799,"totalTrials":238,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2265,"PHASE4":2267,"NA":2269},{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[2261],{"nctId":788,"briefTitle":789,"status":282,"phases":2262,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":2263,"interventions":2264},[87],[796,797],[799,533],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[2271],{"nctId":2272,"briefTitle":2273,"status":282,"phases":2274,"primaryCompletion":876,"completion":2275,"start":2276,"enrollment":2277,"conditions":2278,"interventions":2279},"NCT02582320","Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program",[],"2018-10-03","2016-03",264,[15],[799],{"intervention":1930,"totalTrials":238,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2294,"NA":2296},{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[],{"trials":2287,"activeCount":98},[],{"trials":2289,"activeCount":98},[2290],{"nctId":2060,"briefTitle":2061,"status":282,"phases":2291,"primaryCompletion":2063,"completion":2063,"start":2064,"enrollment":2065,"conditions":2292,"interventions":2293},[88],[2067],[1930,638],{"trials":2295,"activeCount":98},[],{"trials":2297,"activeCount":98},[2298],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2299,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2300,"interventions":2301},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":744,"totalTrials":238,"cells":2303},{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2316,"NA":2318},{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[2312],{"nctId":735,"briefTitle":736,"status":282,"phases":2313,"primaryCompletion":738,"completion":738,"start":739,"conditions":2314,"interventions":2315},[88],[741,742],[724,744],{"trials":2317,"activeCount":98},[],{"trials":2319,"activeCount":98},[2320],{"nctId":2321,"briefTitle":2322,"status":337,"phases":2323,"primaryCompletion":2324,"completion":2325,"start":2326,"conditions":2327,"interventions":2329},"NCT00449319","AML Treatment in Untreated Adult Patients",[90],"2018-06","2018-07","1998-11",[2328],"Leukemia, Myelocytic, Acute",[744],{"intervention":2331,"totalTrials":94,"cells":2332},"Fostamatinib",{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2341,"NA":2343},{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[2345],{"nctId":2346,"briefTitle":2347,"status":282,"phases":2348,"primaryCompletion":2349,"completion":2349,"start":2350,"enrollment":2351,"conditions":2352,"interventions":2356},"NCT05613296","Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP",[],"2024-05-31","2023-05-05",95,[2353,2354,2355],"ITP - Immune Thrombocytopenia","Chronic ITP","Refractory ITP",[2331],{"intervention":2358,"totalTrials":94,"cells":2359},"IDH mutation test performed at diagnosis or relapse until January 31st, 2019.",{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2364,"PHASE3":2366,"PHASE4":2368,"NA":2370},{"trials":2361,"activeCount":98},[],{"trials":2363,"activeCount":98},[],{"trials":2365,"activeCount":98},[],{"trials":2367,"activeCount":98},[],{"trials":2369,"activeCount":98},[],{"trials":2371,"activeCount":98},[2372],{"nctId":2373,"briefTitle":2374,"status":282,"phases":2375,"primaryCompletion":2376,"completion":2376,"start":1925,"enrollment":2377,"conditions":2378,"interventions":2379},"NCT02986620","Italian Registry on the Prevalence of IDH1\u002FIDH2 Mutations in Patients With Acute Myeloid Leukemia",[],"2021-03-22",388,[33],[2358],{"intervention":2381,"totalTrials":94,"cells":2382},"Dasatinib and blinatumomab",{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[2395],{"nctId":2396,"briefTitle":2397,"status":337,"phases":2398,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":842,"conditions":2401,"interventions":2402},"NCT03318770","Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[],"2024-05","2019-05-10",[25],[2381],{"intervention":2404,"totalTrials":94,"cells":2405},"Bendamustine + Rituximab",{"EARLY_PHASE1":2406,"PHASE1":2408,"PHASE2":2410,"PHASE3":2412,"PHASE4":2414,"NA":2416},{"trials":2407,"activeCount":98},[],{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[],{"trials":2413,"activeCount":98},[],{"trials":2415,"activeCount":98},[],{"trials":2417,"activeCount":98},[2418],{"nctId":2419,"briefTitle":2420,"status":282,"phases":2421,"primaryCompletion":2422,"completion":2422,"start":2063,"enrollment":2423,"conditions":2424,"interventions":2425},"NCT02491398","Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia",[],"2017-01",494,[15],[2404],{"intervention":2427,"totalTrials":94,"cells":2428},"Vincristine",{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2437,"NA":2439},{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[],{"trials":2434,"activeCount":98},[],{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[],{"trials":2440,"activeCount":98},[2441],{"nctId":2442,"briefTitle":2443,"status":282,"phases":2444,"completion":2445,"start":2446,"conditions":2447,"interventions":2449},"NCT00537550","Adult ALL Treatment at Diagnosis",[90],"2006-06","2000-07",[2448],"Leukemia, Lymphocytic, Acute",[2427,2450],"Vincristin, Daunorubicine, Asparaginase, Methotrexate",{"intervention":2450,"totalTrials":94,"cells":2452},{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2457,"PHASE3":2459,"PHASE4":2461,"NA":2463},{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[],{"trials":2460,"activeCount":98},[],{"trials":2462,"activeCount":98},[],{"trials":2464,"activeCount":98},[2465],{"nctId":2442,"briefTitle":2443,"status":282,"phases":2466,"completion":2445,"start":2446,"conditions":2467,"interventions":2468},[90],[2448],[2427,2450],{"intervention":1931,"totalTrials":94,"cells":2470},{"EARLY_PHASE1":2471,"PHASE1":2473,"PHASE2":2475,"PHASE3":2477,"PHASE4":2479,"NA":2481},{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":98},[],{"trials":2476,"activeCount":98},[],{"trials":2478,"activeCount":98},[],{"trials":2480,"activeCount":98},[],{"trials":2482,"activeCount":98},[2483],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2484,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2485,"interventions":2486},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":1932,"totalTrials":94,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2499},{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"trials":2496,"activeCount":98},[],{"trials":2498,"activeCount":98},[],{"trials":2500,"activeCount":98},[2501],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2502,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2503,"interventions":2504},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":1933,"totalTrials":94,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2508,"activeCount":98},[],{"trials":2510,"activeCount":98},[],{"trials":2512,"activeCount":98},[],{"trials":2514,"activeCount":98},[],{"trials":2516,"activeCount":98},[],{"trials":2518,"activeCount":98},[2519],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2520,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2521,"interventions":2522},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":1934,"totalTrials":94,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[],{"trials":2530,"activeCount":98},[],{"trials":2532,"activeCount":98},[],{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[2537],{"nctId":1922,"briefTitle":1923,"status":282,"phases":2538,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1763,"conditions":2539,"interventions":2540},[90],[23],[633,1929,618,634,1930,1931,1932,635,636,637,638,1933,639,1934],{"intervention":2542,"totalTrials":94,"cells":2543},"Venetoclax plus HMA",{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2548,"PHASE3":2550,"PHASE4":2552,"NA":2554},{"trials":2545,"activeCount":98},[],{"trials":2547,"activeCount":98},[],{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[2556],{"nctId":2557,"briefTitle":2558,"status":282,"phases":2559,"primaryCompletion":2560,"completion":2560,"start":2561,"enrollment":2562,"conditions":2563,"interventions":2564},"NCT04589728","Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648\u002F96",[],"2024-09-08","2021-02-23",202,[21],[2542],{"intervention":2566,"totalTrials":94,"cells":2567},"Lamivudine",{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2574,"PHASE4":2576,"NA":2578},{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[],{"trials":2573,"activeCount":98},[],{"trials":2575,"activeCount":98},[],{"trials":2577,"activeCount":98},[],{"trials":2579,"activeCount":98},[2580],{"nctId":2581,"briefTitle":2582,"status":282,"phases":2583,"primaryCompletion":2584,"completion":2585,"start":2586,"enrollment":329,"conditions":2587,"interventions":2588},"NCT03528941","The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib",[],"2021-03-26","2021-06-30","2018-11-28",[15],[2566],{"intervention":2590,"totalTrials":94,"cells":2591},"Antibiotic and antifungal drugs",{"EARLY_PHASE1":2592,"PHASE1":2594,"PHASE2":2596,"PHASE3":2598,"PHASE4":2600,"NA":2602},{"trials":2593,"activeCount":98},[],{"trials":2595,"activeCount":98},[],{"trials":2597,"activeCount":98},[],{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[],{"trials":2603,"activeCount":98},[2604],{"nctId":2605,"briefTitle":2606,"status":282,"phases":2607,"primaryCompletion":2608,"completion":2608,"start":628,"enrollment":2609,"conditions":2610,"interventions":2612},"NCT01951430","Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients",[],"2020-10-29",229,[2611],"Myelodysplastic Syndrome",[2590],{"intervention":2614,"totalTrials":94,"cells":2615},"Fedratinib",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2622,"PHASE4":2624,"NA":2626},{"trials":2617,"activeCount":98},[],{"trials":2619,"activeCount":98},[],{"trials":2621,"activeCount":98},[],{"trials":2623,"activeCount":98},[],{"trials":2625,"activeCount":98},[],{"trials":2627,"activeCount":98},[2628],{"nctId":2629,"briefTitle":2630,"status":337,"phases":2631,"primaryCompletion":2632,"completion":2632,"start":2633,"enrollment":2634,"conditions":2635,"interventions":2639},"NCT05883904","Real World Evidence of Fedratinib Effectiveness in MF",[],"2026-01","2024-01-29",93,[2636,2637,2638],"Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis",[2614],{"intervention":2641,"totalTrials":94,"cells":2642},"idelalisib and rituximab",{"EARLY_PHASE1":2643,"PHASE1":2645,"PHASE2":2647,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2644,"activeCount":98},[],{"trials":2646,"activeCount":98},[],{"trials":2648,"activeCount":98},[],{"trials":2650,"activeCount":98},[],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":98},[2655],{"nctId":2656,"briefTitle":2657,"status":282,"phases":2658,"primaryCompletion":2659,"completion":2659,"start":2660,"enrollment":2661,"conditions":2662,"interventions":2663},"NCT03545035","Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study",[],"2020-10-28","2019-02-06",104,[15],[2641],{"intervention":2123,"totalTrials":94,"cells":2665},{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2674,"NA":2676},{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[],{"trials":2671,"activeCount":98},[],{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[],{"trials":2677,"activeCount":98},[2678],{"nctId":2114,"briefTitle":2115,"status":282,"phases":2679,"primaryCompletion":2117,"completion":2117,"start":2118,"enrollment":2119,"conditions":2680,"interventions":2681},[],[2121],[2078,2123]]